Literature DB >> 20927569

Outcome of treatment and parameters influencing recurrence in patients with bisphosphonate-related osteonecrosis of the jaws.

Thomas Mücke1, Janett Koschinski, Herbert Deppe, Stefan Wagenpfeil, Christoph Pautke, David A Mitchell, Klaus-Dietrich Wolff, Frank Hölzle.   

Abstract

PURPOSE: Bisphosphonate-related osteonecrosis of the jaws (BRONJ) is now a well-recognised entity which is difficult to manage and often recurs. The aim of this study was to examine the success of resection of the necrotic bone and identify risk factors for recurrence in these patients.
METHODS: One hundred and eight patients were evaluated prospectively and investigated at least twice. Multiple logistic regression analysis was used to determine factors independently associated with the dependent variable of recurrence of BRONJ.
RESULTS: Factors influencing the development of recurrence of BRONJ were the presence of bacterial bone infection of the necrotic area (P = 0.011), type of treatment (either conservative or surgical, P = 0.001) with a lower recurrence rate for surgically treated patients, extent of surgical treatment with better outcome in larger resections (P < 0.0001), number of debridements performed (P < 0.0001), and the extent of radiographic appearance of osteolysis assessed by dental panoramic tomogram (P = 0.028).
CONCLUSIONS: An increased risk for recurrence can be found in cases with bacterial bone infection of the necrotic area, type of conservative or surgical treatment, extent of surgical treatment with better outcome in larger resections, and the number of debridements performed. Microvascular tissue transfer should be considered in selected cases if other options have been exhausted.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20927569     DOI: 10.1007/s00432-010-0953-1

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  36 in total

1.  Intravenous bisphosphonates and osteonecrosis.

Authors:  Martin S Greenberg
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2004-09

2.  Bisphosphanates and oral cavity avascular bone necrosis.

Authors:  Cesar A Migliorati
Journal:  J Clin Oncol       Date:  2003-11-15       Impact factor: 44.544

3.  Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy.

Authors:  Cesar A Migliorati; Mark M Schubert; Douglas E Peterson; Luis Marcelo Seneda
Journal:  Cancer       Date:  2005-07-01       Impact factor: 6.860

Review 4.  Bisphosphonates: an overview with special reference to alendronate.

Authors:  S D Vasikaran
Journal:  Ann Clin Biochem       Date:  2001-11       Impact factor: 2.057

5.  Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis.

Authors:  Torsten Hansen; Martin Kunkel; Achim Weber; C James Kirkpatrick
Journal:  J Oral Pathol Med       Date:  2006-03       Impact factor: 4.253

Review 6.  [Bisphosphonate-associated osteonecrosis of the jaw].

Authors:  M H Abu-Id; Y Açil; J Gottschalk; T Kreusch
Journal:  Mund Kiefer Gesichtschir       Date:  2006-03

7.  Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy.

Authors:  Estee P Wang; Leonard B Kaban; Gordon J Strewler; Noopur Raje; Maria J Troulis
Journal:  J Oral Maxillofac Surg       Date:  2007-07       Impact factor: 1.895

8.  Panoramic radiograph, computed tomography or magnetic resonance imaging. Which imaging technique should be preferred in bisphosphonate-associated osteonecrosis of the jaw? A prospective clinical study.

Authors:  Philipp Stockmann; Fabian M Hinkmann; Michael M Lell; Matthias Fenner; Eleftherios Vairaktaris; Friedrich-Wilhelm Neukam; Emeka Nkenke
Journal:  Clin Oral Investig       Date:  2009-06-10       Impact factor: 3.573

9.  Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.

Authors:  Christian Walter; Bilal Al-Nawas; Knut A Grötz; Christian Thomas; Joachim W Thüroff; Viktoria Zinser; Heinold Gamm; Joachim Beck; Wilfried Wagner
Journal:  Eur Urol       Date:  2008-06-26       Impact factor: 20.096

10.  Natural history of osteonecrosis of the jaw in patients with multiple myeloma.

Authors:  Ashraf Badros; Evangelos Terpos; Eirini Katodritou; Olga Goloubeva; Efstathios Kastritis; Evgenia Verrou; Kostas Zervas; Maria R Baer; Timothy Meiller; Meletios A Dimopoulos
Journal:  J Clin Oncol       Date:  2008-11-17       Impact factor: 44.544

View more
  28 in total

1.  Drug holiday as a prognostic factor of medication-related osteonecrosis of the jaw.

Authors:  Yoon Ho Kim; Ho Kyung Lee; Seung Il Song; Jeong Keun Lee
Journal:  J Korean Assoc Oral Maxillofac Surg       Date:  2014-10-24

Review 2.  Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015.

Authors:  A Khan; A Morrison; A Cheung; W Hashem; J Compston
Journal:  Osteoporos Int       Date:  2015-10-22       Impact factor: 4.507

3.  Bisphosphonate-associated osteonecrosis of the mandible: reliable soft tissue reconstruction using a local myofascial flap.

Authors:  Juliana Lemound; Andrè Eckardt; Horst Kokemüller; Constantin von See; Pit Jacob Voss; Frank Tavassol; Martin Rücker; Majeed Rana; Nils-Claudius Gellrich
Journal:  Clin Oral Investig       Date:  2011-08-05       Impact factor: 3.573

Review 4.  Epidemiology and pathogenesis of osteonecrosis of the jaw.

Authors:  Ian R Reid; Jillian Cornish
Journal:  Nat Rev Rheumatol       Date:  2011-11-29       Impact factor: 20.543

Review 5.  [Bisphosphonate-associated osteonecrosis of the jaw].

Authors:  S Koy; M Schubert; J Koy; M Ney; G Lauer; R Sabatowski
Journal:  Schmerz       Date:  2015-04       Impact factor: 1.107

6.  Periosteal reaction of medication-related osteonecrosis of the jaw (MRONJ): clinical significance and changes during conservative therapy.

Authors:  Sakiko Soutome; Mitsunobu Otsuru; Saki Hayashida; Souichi Yanamoto; Miho Sasaki; Yukinori Takagi; Misa Sumi; Yuka Kojima; Shunsuke Sawada; Hiroshi Iwai; Masahiro Umeda; Toshiyuki Saito
Journal:  Support Care Cancer       Date:  2021-04-21       Impact factor: 3.603

7.  Stage-related treatment concept of medication-related osteonecrosis of the jaw-a case series.

Authors:  Petra Rugani; Stephan Acham; Barbara Kirnbauer; Astrid Truschnegg; Barbara Obermayer-Pietsch; Norbert Jakse
Journal:  Clin Oral Investig       Date:  2014-12-17       Impact factor: 3.573

Review 8.  Surgical management of bisphosphonate-related osteonecrosis of the jaws: literature review.

Authors:  Larissa Fernandes Silva; Cláudia Curra; Marcelo Salles Munerato; Carlos Cesar Deantoni; Mariza Akemi Matsumoto; Camila Lopes Cardoso; Marcos Martins Curi
Journal:  Oral Maxillofac Surg       Date:  2015-12-11

9.  Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials.

Authors:  Wei-Xiang Qi; Li-Na Tang; Ai-Na He; Yang Yao; Zan Shen
Journal:  Int J Clin Oncol       Date:  2013-04-20       Impact factor: 3.402

Review 10.  Actinomyces osteomyelitis in bisphosphonate-related osteonecrosis of the jaw (BRONJ): the missing link?

Authors:  J De Ceulaer; E Tacconelli; S J Vandecasteele
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-06-01       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.